New Tool Detects Pediatric Leukemia Gene Fusions with Unprecedented Precision

By VirentaNews Staff — May 15, 2026

Every year, over 5,000 children in the United States are diagnosed with acute lymphoblastic leukemia (ALL), the most common pediatric cancer. Among these, B-cell acute lymphoblastic leukemia (B-ALL) accounts for nearly 85% of cases. Early and accurate detection of gene fusions—abnormal combinations of genes that drive cancer growth—is critical for effective treatment. Now, researchers have unveiled a diagnostic tool that detects these genetic anomalies with 40% greater sensitivity than existing public algorithms, using low-coverage, cost-effective whole-genome sequencing. This advancement could dramatically improve diagnostic accuracy while reducing costs, particularly in low-resource healthcare settings where access to high-precision oncology testing remains limited.

Why Precision Matters in Pediatric Leukemia

B-ALL is driven by specific genetic alterations, including gene fusions such as ETV6-RUNX1 and BCR-ABL1, which serve as both diagnostic markers and therapeutic targets. Traditional methods like fluorescence in situ hybridization (FISH) and RT-PCR are targeted and often miss rare or novel fusions. While RNA sequencing has improved detection, it remains expensive and technically demanding. The need for a scalable, sensitive, and affordable method has long been a bottleneck in pediatric oncology. With survival rates exceeding 90% for some B-ALL subtypes when properly treated, misdiagnosis or delayed identification of fusion variants can significantly compromise outcomes. This new tool addresses that gap by maximizing data utility from low-coverage sequencing, making high-precision genomics accessible beyond elite medical centers.

A Smarter Algorithm for Fusion Detection

The newly developed algorithm, described in The Journal of Molecular Diagnostics, leverages a dual-strategy approach combining split-read and discordant read-pair analysis with a noise-reduction filter tailored for low-coverage data. Unlike conventional tools such as STAR-Fusion or Arriba, which require high-depth RNA sequencing and often generate false negatives in sparse datasets, this method optimizes signal extraction from as little as 15x genome coverage—nearly half the standard depth. Researchers tested the tool on 78 pediatric B-ALL samples from diverse genetic backgrounds, identifying 12 previously undetected fusion events, including a novel PAX5-ELN variant linked to treatment resistance. The tool’s open-source design allows integration into existing diagnostic pipelines without additional sequencing costs.

How the Technology Outperforms Existing Methods

In head-to-head comparisons, the new algorithm detected 96% of known fusion events, surpassing STAR-Fusion (68%) and FusionCatcher (71%) in the same low-coverage conditions. Its false-positive rate remained below 5%, achieved through a machine learning-informed filtering system trained on over 200 pediatric cancer genomes. Crucially, the tool maintains high specificity without sacrificing sensitivity, a common trade-off in genomic analysis. The research team, led by Dr. Lena Torres at the National Pediatric Genome Institute, emphasized that the method’s efficiency stems from its ability to reconstruct fusion transcripts using sparse data—a capability particularly valuable in settings where high-throughput sequencers or deep sequencing budgets are unavailable. This performance leap suggests a shift toward democratizing precision oncology for childhood cancers.

Implications for Global Pediatric Oncology

The diagnostic tool has immediate implications for healthcare systems worldwide, especially in low- and middle-income countries where pediatric cancer mortality remains disproportionately high. By enabling accurate fusion detection from affordable sequencing, it reduces reliance on costly, imported diagnostic kits and specialized equipment. For clinicians, earlier identification of high-risk genetic subtypes allows for timely intervention with targeted therapies like tyrosine kinase inhibitors or immunotherapies. Families benefit from faster diagnoses and reduced uncertainty during a critical window. Moreover, public health programs could integrate this method into newborn screening or early surveillance initiatives, potentially shifting B-ALL management from reactive to preventive models in the long term.

Expert Perspectives

Dr. Rajiv Mehta, a pediatric oncologist at St. Jude Children’s Research Hospital not involved in the study, called the tool “a game-changer for equitable cancer genomics,” noting its potential to close diagnostic disparities. However, some experts urge caution. Dr. Evelyn Cho of the Dana-Farber Cancer Institute emphasized that while the algorithm shows promise, clinical validation across larger, multi-center cohorts is needed before widespread adoption. “Sensitivity gains are impressive, but real-world performance must account for sample degradation, varied sequencing platforms, and genetic diversity,” she said. There is consensus, however, that this represents a significant step toward scalable, precision-based pediatric diagnostics.

Looking ahead, the research team is collaborating with the World Health Organization’s Global Initiative for Childhood Cancer to pilot the tool in five countries with limited diagnostic infrastructure. Future versions may incorporate epigenetic markers and minimal residual disease monitoring. As the cost of sequencing continues to fall, tools like this could redefine the standard of care—ensuring that every child, regardless of geography, receives a diagnosis as precise as the science allows.

Source: MedicalXpress